Insulin potentiation therapy

Revision as of 16:26, 9 August 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for Insulin potentiation therapy

Articles

Most recent articles on Insulin potentiation therapy

Most cited articles on Insulin potentiation therapy

Review articles on Insulin potentiation therapy

Articles on Insulin potentiation therapy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Insulin potentiation therapy

Images of Insulin potentiation therapy

Photos of Insulin potentiation therapy

Podcasts & MP3s on Insulin potentiation therapy

Videos on Insulin potentiation therapy

Evidence Based Medicine

Cochrane Collaboration on Insulin potentiation therapy

Bandolier on Insulin potentiation therapy

TRIP on Insulin potentiation therapy

Clinical Trials

Ongoing Trials on Insulin potentiation therapy at Clinical Trials.gov

Trial results on Insulin potentiation therapy

Clinical Trials on Insulin potentiation therapy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Insulin potentiation therapy

NICE Guidance on Insulin potentiation therapy

NHS PRODIGY Guidance

FDA on Insulin potentiation therapy

CDC on Insulin potentiation therapy

Books

Books on Insulin potentiation therapy

News

Insulin potentiation therapy in the news

Be alerted to news on Insulin potentiation therapy

News trends on Insulin potentiation therapy

Commentary

Blogs on Insulin potentiation therapy

Definitions

Definitions of Insulin potentiation therapy

Patient Resources / Community

Patient resources on Insulin potentiation therapy

Discussion groups on Insulin potentiation therapy

Patient Handouts on Insulin potentiation therapy

Directions to Hospitals Treating Insulin potentiation therapy

Risk calculators and risk factors for Insulin potentiation therapy

Healthcare Provider Resources

Symptoms of Insulin potentiation therapy

Causes & Risk Factors for Insulin potentiation therapy

Diagnostic studies for Insulin potentiation therapy

Treatment of Insulin potentiation therapy

Continuing Medical Education (CME)

CME Programs on Insulin potentiation therapy

International

Insulin potentiation therapy en Espanol

Insulin potentiation therapy en Francais

Business

Insulin potentiation therapy in the Marketplace

Patents on Insulin potentiation therapy

Experimental / Informatics

List of terms related to Insulin potentiation therapy


Overview

Insulin potentiation therapy ("IPT") is a controversial alternative medicine therapy that uses Food and Drug Administration-approved cancer fighting drugs in lower doses. It is used by some alternative medicine practitioners to treat cancer and other diseases because the lower dosing of drug eliminates many of the debilitating side effects of conventional chemotherapy. This treatment is also sometimes referred to as "low dose chemotherapy."

Proposed mechanism

Based on a body of scientific evidence (see refereneces), IPT practitioners and proponents have put forth that insulin modifies cancer cells' receptivity to penetration by chemotherapy drugs. It is well known that the hormone insulin, which is created in the pancreas, modulates many of the body's functions at the cellular level and the regulation of blood glucose levels is the best-known example.

Cancer cells secrete their own insulin and insulin-like growth factor (IGF) which work together to consume a body's nutrients to grow cancer. Cancer cell membranes have about sixteen times more insulin and IGF receptors than normal cells and these receptors react with natural or administered insulin. When insulin is administered, the cancer starves for glucose and generates enzyme activity that makes the cell membrane more permeable to chemotherapy drugs. By using the very same mechanisms that cancer cells use to grow and kill people, IPT channels more of the chemotherapy drug into the cancer cells, killing them and leaving normal cells less affected.

Side effects that normally accompany chemotherapy are minimized because the chemotherapy doses can be as little as 10-15% of the standard dose.

The principal proponent of this procedure is Dr. Donato Perez Garcia (1958-), grandson of the discoverer, Dr. Donato Perez Garcia (1896-1971), who claims that IPT is especially effective with breast cancer. He suggests that it is also effective with a number of other cancers, including small-cell lung cancer and prostate cancer. Essentially, if a cancer can be significantly affected by existing chemotherapy drugs, then insulin potentiation therapy may be effective, without major side effects. Steven G. Ayre, MD opened the first clinic in the US providing IPT in November 1999 called Contemporary Medicine.

The original website about IPT is IPTQ.com, run by Chris Duffield Ph.D., a visiting researcher at Stanford University. For an up to date directory of IPT certified practitioners worldwide, go to IPT for Cancer.

Supportative research

Several in-vitro studies (test-tube) have shown how IPT works supporting the informal clinical work that has been conducted on hundreds of patients worldwide.[1][2]

The first clinical trial of IPT for treating breast cancer was done in Uruguay and published in 2003/2004. Insulin combined with low-dose methotrexate (a chemotherapy drug) resulted in greatly increased stable disease, and much reduced progressive disease, compared with insulin or low-dose methotrexate alone.[3]

In 2000, the National Cancer Institute's Cancer Advisory Panel on Complementary and Alternative Medicine (CAPCAM) invited Drs. Perez Garcia and Ayre to present IPT to them as part of the National Cancer Institute's (NCI's) Best Case Series program. The Elka Best Foundation is working to support research and education in this area. The proponents of IPT claim to eliminate side effects of chemotherapy for at least some patients.

Footnotes

  1. Alabaster O, Vonderhaar B, Shafie S (1981). "Metabolic modification by insulin enhances methotrexate cytotoxicity in MCF-7 human breast cancer cells". Eur J Cancer Clin Oncol. 17 (11): 1223–8. PMID 7037424.
  2. Witt K, Huber J, Egleton R, Davis T (2000). "Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect". J Pharmacol Exp Ther. 295 (3): 972–8. PMID 11082431.
  3. Lasalvia-Prisco E, Cucchi S, Vázquez J, Lasalvia-Galante E, Golomar W, Gordon W (2004). "Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients". Cancer Chemother Pharmacol. 53 (3): 220–4. PMID 14655024.

External links

Supportive

Other External LInks

Template:WikiDoc Sources